HC Wainwright Has Positive Forecast for SRPT Q1 Earnings

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Research analysts at HC Wainwright upped their Q1 2025 EPS estimates for shares of Sarepta Therapeutics in a report released on Wednesday, January 15th. HC Wainwright analyst M. Kapoor now expects that the biotechnology company will post earnings per share of $2.45 for the quarter, up from their prior forecast of $2.35. HC Wainwright currently has a “Sell” rating and a $75.00 price target on the stock. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.17 per share. HC Wainwright also issued estimates for Sarepta Therapeutics’ Q4 2025 earnings at $2.85 EPS.

A number of other analysts have also recently issued reports on SRPT. StockNews.com cut Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 20th. Needham & Company LLC restated a “buy” rating and set a $202.00 target price on shares of Sarepta Therapeutics in a research report on Tuesday. Evercore ISI cut their target price on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating on the stock in a report on Thursday, November 7th. Jefferies Financial Group started coverage on shares of Sarepta Therapeutics in a research note on Monday, October 21st. They set a “buy” rating and a $165.00 price target for the company. Finally, Cantor Fitzgerald upgraded shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $152.00 to $167.00 in a research note on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Sarepta Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $178.71.

Sarepta Therapeutics Stock Performance

Shares of SRPT stock opened at $117.06 on Thursday. The stock’s 50-day moving average is $121.75 and its two-hundred day moving average is $130.06. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. Sarepta Therapeutics has a 1 year low of $102.15 and a 1 year high of $173.25. The firm has a market cap of $11.18 billion, a price-to-earnings ratio of 93.65 and a beta of 0.77.

Insider Transactions at Sarepta Therapeutics

In other news, Director Kathryn Jean Boor sold 1,636 shares of the firm’s stock in a transaction on Thursday, December 5th. The stock was sold at an average price of $125.55, for a total value of $205,399.80. Following the completion of the transaction, the director now owns 5,880 shares in the company, valued at $738,234. This trade represents a 21.77 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of Sarepta Therapeutics stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total value of $1,310,820.00. Following the transaction, the director now directly owns 22,840 shares of the company’s stock, valued at $2,851,345.60. This trade represents a 31.49 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 7.70% of the company’s stock.

Hedge Funds Weigh In On Sarepta Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. American Century Companies Inc. raised its stake in Sarepta Therapeutics by 14.1% in the 2nd quarter. American Century Companies Inc. now owns 7,184 shares of the biotechnology company’s stock valued at $1,135,000 after purchasing an additional 889 shares during the last quarter. Oppenheimer Asset Management Inc. boosted its stake in Sarepta Therapeutics by 19.6% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 4,312 shares of the biotechnology company’s stock worth $681,000 after buying an additional 708 shares during the last quarter. Envestnet Asset Management Inc. grew its holdings in Sarepta Therapeutics by 69.1% in the 2nd quarter. Envestnet Asset Management Inc. now owns 68,679 shares of the biotechnology company’s stock valued at $10,851,000 after buying an additional 28,073 shares during the period. WINTON GROUP Ltd acquired a new position in shares of Sarepta Therapeutics during the 2nd quarter valued at about $425,000. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Sarepta Therapeutics by 13.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 255,396 shares of the biotechnology company’s stock worth $40,353,000 after acquiring an additional 31,105 shares during the period. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.